Search results

Journal Article (6)

2018
Journal Article
Möginger, U.; Grunewald, S.; Hennig, R.; Kuo, C.-W.; Schirmeister, F.; Voth, H.; Rapp, E.; Khoo, K.-H.; Seeberger, P. H.; Simon, J.-C. et al.; Kolarich, D.: Alterations of the human skin N- and O-glycome in basal- and squamous cell carcinoma. Frontiers in Oncology 8, 70 (2018)
2016
Journal Article
Lohse, S.; Meyer, S.; Meulenbroek, L. A.P.M.; Jansen, J.H. M.; Nederend, M.; Kretschmer, A.; Klausz, K.; Möginger, U.; Derer, S.; Rösner, T. et al.; Kellner, C.; Schewe, D.; Sondermann, P.; Tiwari, S.; Kolarich, D.; Peipp, M.; Leusen, J. H.W.; Valerius, T.: An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo. Cancer Research 76 (2), pp. 403 - 417 (2016)
Journal Article
Möginger, U.; Resemann, A.; Martin, C. E.; Parameswarappa, S.; Govindan, S.; Wamhoff, E.-C.; Broecker, F.; Suckau, D.; Pereira, C. L.; Chakkumkal, A. et al.; Seeberger, P. H.; Kolarich, D.: Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites. Scientific Reports 6, 20488 (2016)
2014
Journal Article
Marco-Ramell, A.; Miller, I.; Nöbauer, K.; Möginger, U.; Segales, J.; Razzazi-Fazeli, E.; Kolarich, D.; Bassols, A.: Proteomics on porcine haptoglobin and IgG/IgA show protein species distribution and glycosylation pattern to remain similar in PCV2-SD infection. Journal of Proteomics 101, pp. 205 - 216 (2014)
2013
Journal Article
Leymarie, N.; Griffin, P. J.; Jonscher, K.; Kolarich, D.; Orlando, R.; McComb, M.; Zaia, J.; Aguilan, J.; Alley, W. R.; Altmann, F. et al.; Ball, L. E.; Basumallick, L.; Bazemore-Walker, C. R.; Behnken, H.; Blank, M. A.; Brown, K. J.; Bunz, S.-C.; Cairo, C. W.; Cipollo, J. F.; Daneshfar, R.; Desaire, H.; Drake, R. R.; Go, E. P.; Goldman, R.; Gruber, C.; Halim, A.; Hathout, Y.; Hensbergen, P. J.; Horn, D. M.; Hurum, D.; Jabs, W.; Larson, G.; Ly, M.; Mann, B. F.; Marx, K.; Mechref, Y.; Meyer, B.; Moeginger, U.; Neusuess, C.; Nilsson, J.; Novotny, M. V.; Nyalwidhe, J. O.; Packer, N. H.; Pompach, P.; Reiz, B.; Resemann, A.; Rohrer, J. S.; Ruthenbeck, A.; Sanda, M.; Schulz, J. M.; Schweiger-Hufnagel, U.; Sihlbom, C.; Song, E.; Staples, G. O.; Suckau, D.; Tang, H.; Thaysen-Andersen, M.; Viner, R. I.; An, Y.; Valmuv, L.; Wada, Y.; Watson, M.; Windwarder, M.; Whittal, R.; Wuhrer, M.; Zhu, Y.; Zou, C.: Interlaboratory Study on Differential Analysis of Protein Glycosylation by Mass Spectrometry: The ABRF Glycoprotein Research Multi-Institutional Study 2012. MOLECULAR & CELLULAR PROTEOMICS 12 (10), pp. 2935 - 2951 (2013)
Journal Article
Mosca, S.; Dannehl, C.; Möginger, U.; Brezesinski, G.; Hartmann, L.: β(3R3)-Peptides: design and synthesis of novel peptidomimetics and their self-assembling properties at the air-water interface. Organic & Biomolecular Chemistry 11 (33), pp. 5399 - 5403 (2013)

Meeting Abstract (3)

2016
Meeting Abstract
Kretschmer, A.; Lohse, S.; Meyer, S.; Meulenbroek, L.A.P.M.; Jansen, J.H.M.; Möginger, U.; Sondermann, P.; Kolarich, D.; Leusen, J.H.W.; Valerius, T.: Glyco- and Fc engineering of IgA antibodies for cancer immunotherapy improved pharmacokinetics & myeloid effector cell engagement. In Oncology Research and Treatment, 39 (Suppl. 3), P276, pp. 83 - 84. Jahrestagung der ­Deutschen, Österreichischen und ­Schweizerischen ­Gesellschaften für Hämatologie und ­Medizinische Onkologie, Leipzig, October 14, 2016 - October 18, 2016. Karger, Basel, Schweiz (2016)
Meeting Abstract
Rösner, T.; Kretschmer, A.; Lohse, S.; Meyer, S.; Jansen, J. H. M.; Möginger, U.; Sondermann, P.; Kolarich, D.; Leusen, J. H. W.; Valerius, T.: Improvement of pharmacokinetics and myeloid effector cell engagement in vivo by Fc-engineering of IgA antibody against the epidermal growth factor receptor. In European Journal of Cancer, 69, 440, p. S144. Pergamon, Oxford, UK (2016)
2015
Meeting Abstract
Valerius, T.; Lohse, S.; Meyer, S.; Jansen, M. J.H.; Meulenbroek, L. A.P.; Nederend, M.; Möginger, U.; Kretschmer, A.; Klausz, K.; Derer, S. et al.; Sondermann, P.; Kolarich, D.; Peipp, M.; Leusen, J. H.W.; Gramatzki, M.: Pharmacokinetics and myeloid effector cell engagement of an engineered IgA antibody against the epidermal growth factor receptor. In Journal of Clinical Oncology, 33 supplement Ed., abstract 3037. 2015 ASCO Annual Meeting. Grune & Stratton, New York, NY (2015)
Go to Editor View